Understanding how arginine methylation affects cell functions
Resolving cellular functions of arginine methylation
This study is looking at how a special enzyme called PRMT5 helps proteins work properly in our cells, especially in cancer and brain diseases, to see if it could be a good target for new treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Polytechnic Inst and St Univ NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project ID | NIH-11112537 on NIH RePORTER |
What this research studies
This research investigates the role of PRMT5, an enzyme that modifies proteins by adding methyl groups to arginine residues, which is crucial for various cellular processes. The study aims to uncover how these modifications influence protein interactions, mRNA binding, and overall cell survival, particularly in the context of cancer and neurodegenerative diseases. By identifying the specific functions and substrates of PRMT5, the research seeks to clarify its importance in maintaining healthy cellular functions and its potential as a therapeutic target.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cancer or neurodegenerative diseases who may benefit from targeted therapies.
Not a fit: Patients with conditions unrelated to cellular functions or those not affected by arginine methylation may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating cancers and neurodegenerative diseases by targeting PRMT5.
How similar studies have performed: Previous research has shown that targeting similar biochemical pathways can lead to significant advancements in cancer treatment, suggesting a promising avenue for this investigation.
Where this research is happening
Blacksburg, United States
- Virginia Polytechnic Inst and St Univ — Blacksburg, United States (Active)
Researchers
- Principal investigator: Mulvaney, Kathleen — Virginia Polytechnic Inst and St Univ
- Study coordinator: Mulvaney, Kathleen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.